Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy

Am J Kidney Dis. 2018 Dec;72(6):906. doi: 10.1053/j.ajkd.2018.07.013. Epub 2018 Sep 17.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Glomerulonephritis, Membranoproliferative*
  • Humans
  • Kidney Diseases*
  • Standard of Care

Substances

  • Antibodies, Monoclonal, Humanized
  • eculizumab